Another Phase II clinical trial evaluating the efficacy of a VEGFR inhibitor and a PD-L1 inhibitor in recurrent/metastatic ACC patients reported a confirmed ORR of 18% (20). Here, CD274 is linked to adrenal cortex carcinoma.